Myocardial perfusion imaging

Cleerly® ISCHEMIA™ Demonstrates Robust Diagnostic Accuracy and Prognostic Utility in Analyses from Large Scale Clinical Trials

Retrieved on: 
星期四, 三月 28, 2024
FDA, Health, Technology, Clinical Trials, Artificial Intelligence, Cardiology, Diagnosis, Coronary ischemia, Patient, Myocardial perfusion imaging, Journal, Ischemia, MD, American College, CCTA, Stenosis, Atherosclerosis, SPECT, Medical device

The study describes the validation of Cleerly's artificial intelligence-guided quantitative coronary CT angiography (AI-QCT) ISCHEMIA technology for diagnostic accuracy and prognostic risk stratification.

Key Points: 
  • The study describes the validation of Cleerly's artificial intelligence-guided quantitative coronary CT angiography (AI-QCT) ISCHEMIA technology for diagnostic accuracy and prognostic risk stratification.
  • For patients with an abnormal Cleerly AI-QCT ISCHEMIA finding, a positive result was associated with an approximately 7-fold increase of adverse cardiovascular events during an 8-year follow-up.
  • Collectively, this study shows that Cleerly AI-QCT ISCHEMIA, when used in conjunction with Cleerly LABS, can provide a 3-in-1 approach for the assessment of atherosclerosis, stenosis and ischemia.
  • These study results come after Cleerly announced that its Cleerly ISCHEMIA software device is billable using the new Category I CPT® code 75580.

Lantheus Announces the FDA Approval of DEFINITY® (Perflutren Lipid Microsphere) for Pediatric Patients

Retrieved on: 
星期一, 三月 4, 2024
Kawasaki disease, Birth, Headache, Doctor of Philosophy, Radiology, Aes, Combat, MD, Myocardial perfusion imaging, FDA, Food, Dizziness, Cardiology, Shanda, Heart rate, Nausea, LNTH, Safety, Fatigue, Kawasaki, Golding, Patient, Heart, All, Diagnosis, Male, Movement

This approval represents a significant step forward in pediatric medicine, providing healthcare professionals with a valuable tool to opacify the left ventricular chamber and better identify the left ventricular endocardial border.

Key Points: 
  • This approval represents a significant step forward in pediatric medicine, providing healthcare professionals with a valuable tool to opacify the left ventricular chamber and better identify the left ventricular endocardial border.
  • Currently, DEFINITY is the most utilized, extensively studied, and a trusted diagnostic ultrasound enhancing agent in the U.S.1-3
    “The expanded indication for DEFINITY is a testament to the rigorous research and development efforts undertaken by Lantheus to address unmet medical needs of pediatric patients,” said Jean-Claude Provost, MD, Chief Medical Officer.
  • “We are proud that this approval will extend the benefits of DEFINITY to healthcare professionals who work with these young individuals.”
    Clinical studies have substantiated the efficacy and safety of DEFINITY in pediatric patients.
  • The Kutty and Fine studies each reported successful left ventricular opacification in all participants.

Cleerly® Announces CERTAIN Multicenter Clinical Trial Results

Retrieved on: 
星期四, 二月 8, 2024
Health, Clinical Trials, Cardiology, Other Health, Drug, Ischemia, MD, American College, Derivation, Cole, Detection, Medicine, Intelligence, Artificial intelligence, Coronary ischemia, Science, Atherosclerosis, Society, CCTA, Myocardial perfusion imaging, PMID, Plaque, SPECT, PET, FDA, Adenosine, American Journal of Roentgenology, Diagnosis, Patient, Stenosis, Moyamoya disease, Validation, Splenic infarction, Physician, Health literacy, Journal, Coronary artery disease, Coronary, Medical imaging

These results underscore the strong and positive effect of the Cleerly products on clinical utility for patients with suspected coronary artery disease.

Key Points: 
  • These results underscore the strong and positive effect of the Cleerly products on clinical utility for patients with suspected coronary artery disease.
  • In all multicenter and single clinical studies performed to date, Cleerly’s products have consistently demonstrated robust clinical utility, including higher diagnostic accuracy and stronger prognostic risk stratification over such historical tests as nuclear SPECT stress testing and FFRCT2-7.
  • Cleerly’s approach is grounded in science, based on over 10 million images from over 40,000 patients gathered over a 15-year-period in landmark, multi-center clinical trials.
  • Led by a world-class clinical and technical team, Cleerly enhances health literacy for each and every stakeholder in the coronary care pathway.

US Nuclear’s Medical Isotope Production to Revolutionize Healthcare

Retrieved on: 
星期二, 一月 30, 2024
Isotope, Myocardial perfusion imaging, Nuclear medicine, US Nuclear Corp, Health, Diagnosis, Medicine, Facial muscles, United, Approximation error, Risk, Tissue, Google Images, Medical imaging

US Nuclear’s (OTC-QB: UCLE) plan to bring medical isotopes to the market will reshape the landscape of healthcare and diagnostic imaging.

Key Points: 
  • US Nuclear’s (OTC-QB: UCLE) plan to bring medical isotopes to the market will reshape the landscape of healthcare and diagnostic imaging.
  • Medical isotopes play a key role in various diagnostic and therapeutic applications, aiding in the detection and treatment of numerous medical conditions.
  • One of the most important functions of these isotopes is providing precise and accurate diagnostics for various medical conditions.
  • With the increased medical isotope production capacity provided by US Nuclear, people across the world in other countries can have access to these critical tools, addressing healthcare disparities and improving lives.

GE Healthcare and Lantheus Phase III Clinical Trial Finds [18F]flurpiridaz PET Radiotracer Could Improve Detection of Coronary Artery Disease

Retrieved on: 
星期二, 九月 13, 2022
Science, Cardiology, Biotechnology, Research, Pharmaceutical, Health, Medical Devices, Clinical Trials, Photon, Single-photon emission computed tomography, Half-life, American Society of Nuclear Cardiology, St. Luke's Hospital, Development, Molecular imaging, Thomas Edison, Twitter, NYSE, MPI, Phase, Research, Hospital, LinkedIn, Society, News, Coronary artery disease, Patient, Intelligence, PET, LNTH, 18F, Luke the Evangelist, Myocardial perfusion imaging, Research and development, Cardiology, Doctor of Philosophy, CAD, Ecosystem, NASDAQ, Death, Neurology, SPECT, GE Healthcare, Congress, Multimedia, ASNC, FACC, Positron emission tomography, Medical imaging, Pharmaceutical industry, MD, Facebook

GE Healthcare and Lantheus Holdings Inc (NASDAQ: LNTH) have announced that the recent Phase III clinical trial of their investigational radiotracer, [18F]flurpiridaz, has met its co-primary endpoints of exceeding a 60 percent threshold for both sensitivity and specificity for detecting Coronary Artery Disease (CAD).

Key Points: 
  • GE Healthcare and Lantheus Holdings Inc (NASDAQ: LNTH) have announced that the recent Phase III clinical trial of their investigational radiotracer, [18F]flurpiridaz, has met its co-primary endpoints of exceeding a 60 percent threshold for both sensitivity and specificity for detecting Coronary Artery Disease (CAD).
  • Dr. Francois Tranquart, MD, PhD, Global Head of Clinical Development for GE Healthcare Pharmaceutical Diagnostics, Research and Development, said: The positive Phase III trial results are a key step towards future approval of Flurpiridaz (18F) Injection as a potential new cardiac PET agent which could improve the detection of coronary artery disease.
  • This is another example of GE Healthcare investing in our portfolio of Molecular Imaging products to help improve diagnostic accuracy and patient outcomes.
  • GE Healthcare is the $17.7 billion healthcare business of GE (NYSE: GE).

GE Healthcare and Lantheus Phase III Clinical Trial Finds [18F]flurpiridaz PET Radiotracer Could Improve Detection of Coronary Artery Disease

Retrieved on: 
星期二, 九月 13, 2022
Photon, Single-photon emission computed tomography, Half-life, NORTH, American Society of Nuclear Cardiology, St. Luke's Hospital, Development, Molecular imaging, Thomas Edison, Twitter, NYSE, MPI, Phase, Research, Hospital, LinkedIn, Society, News, Coronary artery disease, Program, Patient, Intelligence, PET, LNTH, 18F, Myocardial perfusion imaging, Luke the Evangelist, Research and development, Cardiology, Doctor of Philosophy, CAD, Ecosystem, NASDAQ, Death, Neurology, SPECT, GLOBE, GE Healthcare, Congress, ASNC, FACC, Positron emission tomography, Medical imaging, Pharmaceutical industry, MD, Facebook

Dr. Francois Tranquart, MD, PhD, Global Head of Clinical Development for GE Healthcare Pharmaceutical Diagnostics, Research and Development, said: The positive Phase III trial results are a key step towards future approval of Flurpiridaz (18F) Injection as a potential new cardiac PET agent which could improve the detection of coronary artery disease.

Key Points: 
  • Dr. Francois Tranquart, MD, PhD, Global Head of Clinical Development for GE Healthcare Pharmaceutical Diagnostics, Research and Development, said: The positive Phase III trial results are a key step towards future approval of Flurpiridaz (18F) Injection as a potential new cardiac PET agent which could improve the detection of coronary artery disease.
  • This is another example of GE Healthcare investing in our portfolio of Molecular Imaging products to help improve diagnostic accuracy and patient outcomes.
  • GE Healthcare has led the funding and development of [18F]flurpiridaz, and, if the imaging agent is approved, will have global commercialization rights.
  • GE Healthcare is the $17.7 billion healthcare business of GE (NYSE: GE).

Outlook on the Coronary Heart Disease Diagnostic Imaging Devices Global Market to 2030 - Featuring GE Healthcare, Fujifilm, Siemens Healthineer and Toshiba Among Others - ResearchAndMarkets.com

Retrieved on: 
星期二, 七月 19, 2022
Health, Medical Devices, Cardiology, Chapter Three, CZT, Acquisition, Patient, CT scan, Hospital, CTCA, National Association Medical Staff Services, CVD, CAGR, Asia-Pacific, Moyamoya disease, Diabetes, Technology, Adoption, Computed tomography angiography, Hypertension, Myocardial perfusion imaging, Death, CHD, Medical imaging, COVID-19, Risk, Growth, Nuclear medicine, Diagnosis, PET, SPECT, Coronary artery disease, Pharmaceutical industry

For instance, intravascular ultrasound, X-ray angiography, and computed tomography angiography (CTCA) provide a direct evaluation and quantification of alterations in the coronary arteries.

Key Points: 
  • For instance, intravascular ultrasound, X-ray angiography, and computed tomography angiography (CTCA) provide a direct evaluation and quantification of alterations in the coronary arteries.
  • The coronary heart disease diagnostic imaging devices market saw a sharp decline in 2020, due to the outbreak of the COVID-19 pandemic.
  • Thus, the pandemic significantly impacted the market in 2020, which is likely to stabilize and grow exponentially by 2022.
  • Coronary Heart Disease Diagnostic Imaging Devices Market Variables, Trends & Scope

Dennis A. Calnon, MD, MASNC, Installed as ASNC's President for 2022

Retrieved on: 
星期二, 一月 4, 2022
ASNC, Virginia School for Girls, Executive Council, Journal of Nuclear Cardiology, Efficiency, MPH, Society, Past, Master of Science, Penn State College of Engineering, Engineering, Methodist Hospital, Cardiology, University, Address, MPI, Cardiac amyloidosis, SPECT, PET, Physician, University of Virginia School of Medicine, Pennsylvania State University, American Society of Nuclear Cardiology, Myocardial perfusion imaging, Health, Infection, Patient, Journal, Fair Employment Practice Committee, Cardia (Thrace), Renewable energy, Medical imaging, Management, MD

FAIRFAX, Va., Jan. 4, 2022 /PRNewswire-PRWeb/ --Dennis Calnon, MD, MASNC, nuclear cardiologist and director of cardiac imaging at the OhioHealth Riverside Methodist Hospital in Columbus, was installed as president of the American Society of Nuclear Cardiology (ASNC) for 2022.

Key Points: 
  • FAIRFAX, Va., Jan. 4, 2022 /PRNewswire-PRWeb/ --Dennis Calnon, MD, MASNC, nuclear cardiologist and director of cardiac imaging at the OhioHealth Riverside Methodist Hospital in Columbus, was installed as president of the American Society of Nuclear Cardiology (ASNC) for 2022.
  • He cited the unrivaled versatility and feasibility of myocardial perfusion imaging (MPI) and the trust the modality has earned from clinicians for guiding their patients' care.
  • Regarding threats the specialty may face in the future, Dr. Calnon emphasized ASNC's strengths and highlighted the Society's #PatientFirst philosophy .
  • He will co-direct the new virtual program Nuclear Cardiology NOW: Strategies for Optimization, Efficiency and Productivity on March 11-13, 2022.

Adler Institute for Advanced Imaging Introduces PET/CT Myocardial Perfusion Imaging With N-13 Ammonia To Area Physicians At Their Jenkintown, Pa Facility

Retrieved on: 
星期四, 十月 28, 2021
MRI, MD, CFR, Dementia, Technology, Diagnosis, Degenerative disease, Hospital, Cancer, Myocardial perfusion imaging, Cyclotron, Heart, Cardiac PET, CAD, Ammonia, PET, Medicine, Patient, MBF, Radiopharmaceutical, FDA, View, Adler, Physician, Microangiopathy, CT, COVID-19, Multimedia, Radiation exposure, Coronary artery disease, Half-life, Health, Miniaturization, MACE, Mathematics, Cardiology, PET/CT, N-13, Medical imaging

Adler Imaging is able to offer increased speed and access for cardiac PET/CT scanning on demand.

Key Points: 
  • Adler Imaging is able to offer increased speed and access for cardiac PET/CT scanning on demand.
  • Adler Imaging is one of only five sites nationwide to offer this latest advancement in outpatient cardiac imaging to patients and their doctors in their convenient outpatient office in Jenkintown.
  • For more information about Adler Imaging or PET/CT MYOCARDIAL PERFUSION IMAGING WITH N-13 AMMONIA, please call 215-935-0030or visit https://www.adlerimaging.com .
  • The Adler Institute for Advanced Imaging offers the latest innovation in high tech medical imaging, a combined positron emission tomography (PET) and computed tomography (CT) scanner.

Global Technetium Market (2021 to 2026) - Featuring American Elements, Bayer and Covidien Among Others - ResearchAndMarkets.com

Retrieved on: 
星期一, 十月 25, 2021
Health, Chemicals, Plastics, Manufacturing, Other Health, Radiology, Other Manufacturing, Biotechnology, Neutron, Technetium, COVID-19, Nuclear medicine, Acute coronary syndrome, Particle, Bone, Geography, Industry, Nuclear fission product, Radionuclide, Organization, PET, Particle accelerator, Myocardial perfusion imaging, Biology, LVAD, Government, Metal powder, Coronary heart disease, susceptibility to, 8, Brain, Investment, Fault, Deep vein thrombosis, Growth, Inflammation, Nuclear Medicine and Biology, SPECT, Thrombus, Employment, Pulmonary embolism, Medical imaging

This report provides deep insights into the current and future state of the technetium market across various regions.

Key Points: 
  • This report provides deep insights into the current and future state of the technetium market across various regions.
  • The report examines the market drivers and restraints, along with the impact of Covid-19 on the market's growth, in detail.
  • According to the publisher, the global technetium market is expected to witness growth at a considerable rate during the forecast period.
  • Boasting high development, North America has been the largest market for global technetium due to the demand for advanced medical facilities here.